Loading
A phase 1/2 trial of Fludarabine, Cyclophosphamide in melanoma and uveal melanoma, run by Beijing Biotech, now recruiting.
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma is a phase 1/2 interventional study registered as NCT07627698 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-06-14. Interventions recorded: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide. Conditions listed: Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/